Mark Schiffman1, Laurence M Vaughan2, Tina R Raine-Bennett3, Philip E Castle4, Hormuzd A Katki5, Julia C Gage5, Barbara Fetterman6, Brian Befano7, Nicolas Wentzensen5. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA. Electronic address: schiffmm@mail.nih.gov. 2. BD Diagnostics, Sparks, MD, USA. 3. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, The Bronx, NY, USA. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA. 6. Kaiser Regional Laboratory, Berkeley, CA, USA. 7. Information Management Systems, Inc., Calverton, MD, USA.
Abstract
BACKGROUND: In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US (equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead. METHODS: The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median follow-up is 3.0years. Using stratified random sampling, we typed 2079 archived enrollment specimens including 329 women subsequently diagnosed with CIN3+, 563 with CIN2, and 1187 with <CIN2. Adjusting for sampling, we computed 3-year cumulative CIN3+ risks for each Onclarity typing channel, using Kaplan-Meier methods. RESULTS: The 3-year CIN3+ risk for all HC2-positive women with ASC-US was 5.2%; this establishes the "benchmark" risk for colposcopic referral. Hierarchically, 3-year cumulative risks for each typing channel were 16.0% for HPV16, 7.4% for HPV18, 7.0% for HPV31, 7.1% for grouped HPV33/58, 4.3% for HPV52, 3.9% for HPV45, 2.7% for HPV51, 1.6% for HPV39/68/35, and 1.3% for HPV59/56/66. DISCUSSION: ASC-US linked to HPV16, HPV18, HPV31, or HPV33/58 warrants immediate colposcopy. Optimal management of women with HPV52 or HPV45 is uncertain. Risk of women with only HPV51, HPV39/68/35, or HPV59/56/66 might be low enough to recommend 1-year retesting permitting viral clearance. This strategy would defer colposcopy for 40% of women with HPV-positive ASC-US, half of whom would be cotest-negative at 1-year return. Approximately 10% of those with CIN3 diagnosable at enrollment would be delayed 1year instead. Cost-effectiveness analyses are needed. Published by Elsevier Inc.
BACKGROUND: In US cervical screening, immediate colposcopy is recommended for women with HPV-positive ASC-US (equivocal) cytology. We evaluated whether partial typing by Onclarity™ (BD) might identify HPV-positive women with low enough CIN3+ risk to permit 1-year follow-up instead. METHODS: The NCI-Kaiser Permanente Northern California Persistence and Progression cohort includes a subset of 13,890 women aged 21+ with HC2 (Qiagen)-positive ASC-US at enrollment; current median follow-up is 3.0years. Using stratified random sampling, we typed 2079 archived enrollment specimens including 329 women subsequently diagnosed with CIN3+, 563 with CIN2, and 1187 with <CIN2. Adjusting for sampling, we computed 3-year cumulative CIN3+ risks for each Onclarity typing channel, using Kaplan-Meier methods. RESULTS: The 3-year CIN3+ risk for all HC2-positive women with ASC-US was 5.2%; this establishes the "benchmark" risk for colposcopic referral. Hierarchically, 3-year cumulative risks for each typing channel were 16.0% for HPV16, 7.4% for HPV18, 7.0% for HPV31, 7.1% for grouped HPV33/58, 4.3% for HPV52, 3.9% for HPV45, 2.7% for HPV51, 1.6% for HPV39/68/35, and 1.3% for HPV59/56/66. DISCUSSION: ASC-US linked to HPV16, HPV18, HPV31, or HPV33/58 warrants immediate colposcopy. Optimal management of women with HPV52 or HPV45 is uncertain. Risk of women with only HPV51, HPV39/68/35, or HPV59/56/66 might be low enough to recommend 1-year retesting permitting viral clearance. This strategy would defer colposcopy for 40% of women with HPV-positive ASC-US, half of whom would be cotest-negative at 1-year return. Approximately 10% of those with CIN3 diagnosable at enrollment would be delayed 1year instead. Cost-effectiveness analyses are needed. Published by Elsevier Inc.
Authors: Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman Journal: J Clin Microbiol Date: 2011-06-01 Impact factor: 5.948
Authors: Brandon J LaMere; Janet Kornegay; Barbara Fetterman; Mark Sadorra; Jen Shieh; Philip E Castle Journal: J Virol Methods Date: 2007-07-27 Impact factor: 2.014
Authors: M Arbyn; P J F Snijders; C J L M Meijer; J Berkhof; K Cuschieri; B J Kocjan; M Poljak Journal: Clin Microbiol Infect Date: 2015-05-01 Impact factor: 8.067
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney Journal: J Low Genit Tract Dis Date: 2013-04 Impact factor: 1.925
Authors: Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch Journal: Lancet Oncol Date: 2010-10-15 Impact factor: 41.316
Authors: J Cuzick; L Cadman; D Mesher; J Austin; L Ashdown-Barr; L Ho; G Terry; S Liddle; C Wright; D Lyons; A Szarewski Journal: Br J Cancer Date: 2013-01-31 Impact factor: 7.640
Authors: Maria Demarco; Olivia Carter-Pokras; Noorie Hyun; Philip E Castle; Xin He; Cher M Dallal; Jie Chen; Julia C Gage; Brian Befano; Barbara Fetterman; Thomas Lorey; Nancy Poitras; Tina R Raine-Bennett; Nicolas Wentzensen; Mark Schiffman Journal: J Clin Microbiol Date: 2018-04-25 Impact factor: 5.948
Authors: Joel Fokom Domgue; Mark Schiffman; Nicolas H Wentzensen; Julia C Gage; Philip E Castle; Tina R Raine-Bennett; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Brian Befano; Yi Xie; Lais S Miachon; Michael Dean Journal: J Clin Microbiol Date: 2017-05-17 Impact factor: 5.948
Authors: Asrar Mohammed Abdullah Abdulaziz; Lu Liu; Yu Sun; Xuewu You; Baoxia Cui; Sai Han; Youzhong Zhang Journal: Int J Clin Exp Pathol Date: 2020-02-01
Authors: Thomas C Wright; Mark H Stoler; Valentin Parvu; Karen Yanson; Karen Eckert; Salma Kodsi; Charles K Cooper Journal: Am J Clin Pathol Date: 2019-01-01 Impact factor: 2.493